Skip to content
value.today
Milestone Scientific Inc. logo

Milestone Scientific Inc.

MLSS
$31 Mmarket cap on Oct 14, 2026-41.9% since Jan 2024
Compare
World rank
#22,971
Revenue
$9 M
For year ending December-2025
Net income
$-6 M
-63.8% margin
SEC filing
Employees
15
As of December 31, 2025
SEC filing

Milestone Scientific Inc. in brief

Milestone Scientific Inc. is a listed company in the Medical Instruments industry, based in Livingston, New Jersey, USA. Its market value was $31 M on 14 October 2026, which makes it the 22,971st largest listed company in the world and the 4,034th largest in the USA on this site. In the year to December 2025 it had sales of $9 M and a net loss of $6 M. It employs about 15 people. Its largest product and service lines by sales in 2025 were Handpieces (80%) and Instruments (20%). By market, the largest shares of its 2025 sales came from USA (55%) and China (3%). Its shares trade under the symbol MLSS (NYSE).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Milestone Scientific Inc.

Milestone Scientific Inc. was incorporated in the State of Delaware in August 1989. The Company develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures.

The Company’s core technology platform, Dynamic Pressure Sensing® Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the Company’s dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections.

From the company's annual report filed with the US SEC: read the report

Milestone Scientific Inc. timeline

4 events, 1996–2021
  1. 1996
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 1997
  4. ✎
    Renamed Milestone Scientific Inc
    Formerly U S Opportunity Search Inc.
  5. 2015
  6. 🔔
    · approximate
    Initial public offering on NYSE
  7. 2021
  8. 💰
    Record revenue of $10 million
    FY2021, the highest of the 8 years on record.

Events of Milestone Scientific Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$38 M$77 M$115 M$153 M2020202120222023202420252026

World rank over time

▼ down 2,363 places since 2020
2020-01-01: #20703#20,70320202021-01-01: #17038#17,03820212022-01-07: #21132#21,13220222022-12-25: #27429#27,42920222023-07-30: #23014#23,01420232024-01-05: #24591#24,59120242026-03-08: #11987#11,98720262026-08-01: #19798#19,79820262026-10-14: #23066#23,0662026

Rank in USA: #3,970 (Jan 2020) · #3,505 (Jan 2021) · #4,139 (Jan 2022) · #5,066 (Dec 2022) · #4,425 (Jul 2023) · #4,032 (Jan 2024) · #2,301 (Mar 2026) · #3,773 (Aug 2026) · #4,013 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
3.3×
Price / book
11.0×
Free cash flow yield
-9.5%
Net margin (TTM)
-44.1%
Operating margin
-63.5%
Return on equity
-147.7%
Liabilities / assets
63.9%
Revenue growth
+3.9%
R&D / revenue
5.0%
Revenue per employee
$598 K
Profit per employee
$-381 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $10M, net income $-7M$10MFY18Fiscal year ending Dec 2019: revenue $8M, net income $-8M$8MFY19Fiscal year ending Dec 2020: revenue $5M, net income $-7M$5MFY20Fiscal year ending Dec 2021: revenue $10M, net income $-7M$10MFY21Fiscal year ending Dec 2022: revenue $9M, net income $-9M$9MFY22Fiscal year ending Dec 2023: revenue $10M, net income $-7M$10MFY23Fiscal year ending Dec 2024: revenue $9M, net income $-5M$9MFY24Fiscal year ending Dec 2025: revenue $9M, net income $-6M$9MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$9M+3.9%$-6M$-6M-63.8%
Dec 2024$9M-12.2%$-7M$-5M-54.6%
Dec 2023$10M+11.6%$-7M$-7M-70.5%
Dec 2022$9M-14.5%$-9M$-9M-98.9%
Dec 2021$10M+89.3%$-7M$-7M-66.2%
Dec 2020$5M-35.0%$-7M$-7M-134.9%
Dec 2019$8M-13.0%$-4M$-8M-89.8%
Dec 2018$10M—$-8M$-7M-77.2%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-3M$0M$-3M$-0.07—
Dec 2024$-3M$0M$-3M$-0.06—
Dec 2023$-5M————
Dec 2022$-6M$0M$-6M——
Dec 2021$-4M$0M$-4M$-0.10—
Dec 2020$-7M$0M$-7M$-0.12—
Dec 2019$-2M$0M$-2M$-0.16—
Dec 2018$-2M$0M$-2M$-0.21—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$9M
Net income, trailing 12 months
$-4M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $2M, net income $-2M$2MDec ’24Three months to Mar 2025: revenue $2M, net income $-2M$2MMar ’25Three months to Jun 2025: revenue $2M, net income $-1M$2MJun ’25Three months to Sep 2025: revenue $2M, net income $-1M$2MSep ’25Three months to Dec 2025 (from the annual report): revenue $2M, net income $-1M$2MDec ’25Three months to Mar 2026: revenue $2M, net income $-1M$2MMar ’26Three months to Jun 2026: revenue $3M, net income $-1M$3MJun ’26Three months to Sep 2026: revenue $2M, net income $-1M$2MSep ’26

Latest quarter to Sep 2026: revenue $2M (-5.9% on a year earlier), net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Milestone Scientific Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$9 M
Operating income
$-6 M
Net income
$-6 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$8 M
Total liabilities
$5 M
Total equity
$3 M

As of December-2025

Top 32 institutional investors in Milestone Scientific Inc.#

As of Sep 30, 2026
32 institutions held 5.0 M shares (about 5.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 4.9%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Milestone Scientific Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC2,159,856+86,690 (+4.18%)2.43%$1 MNov 13, 2026
2Geode Capital Management, LLC654,454+10,843 (+1.68%)0.74%$0 MNov 6, 2026
3Vanguard Fiduciary Trust Co464,4490 (0.00%)0.52%$0 MNov 13, 2026
4State Street Corp264,8850 (0.00%)0.30%$0 MNov 12, 2026
5NFSG Corp221,000+80,000 (+56.74%)0.25%$0 MOct 15, 2026
6Citadel Advisors LLC135,051New0.15%$0 MNov 16, 2026
7Northern Trust Corp133,0670 (0.00%)0.15%$0 MNov 16, 2026
8LPL Financial LLC124,9450 (0.00%)0.14%$0 MNov 6, 2026
9Mariner, LLC121,7500 (0.00%)0.14%$0 MNov 12, 2026
10Carnegie Investment Counsel100,1750 (0.00%)0.11%$0 MOct 20, 2026
11Bridgeway Capital Management, LLC97,757-1,743 (-1.75%)0.11%$0 MNov 16, 2026
12Empowered Funds, LLC97,757New0.11%$0 MNov 13, 2026
13BlackRock, Inc.65,4530 (0.00%)0.07%$0 MNov 13, 2026
14XTX Topco Ltd54,339+19,496 (+55.95%)0.06%$0 MNov 16, 2026
15HRT Financial LP51,753New0.06%$0 MNov 13, 2026
16Commonwealth Equity Services, LLC44,7820 (0.00%)0.05%$0 MNov 2, 2026
17Sequoia Financial Advisors, LLC43,4220 (0.00%)0.05%$0 MNov 13, 2026
18Kestra Advisory Services, LLC41,1000 (0.00%)0.05%$0 MNov 2, 2026
19Susquehanna International Group, LLP25,685New0.03%$0 MNov 16, 2026
20Cetera Investment Advisers18,975+1,825 (+10.64%)0.02%$0 MNov 13, 2026
21HighTower Advisors, LLC15,6660 (0.00%)0.02%$0 MNov 10, 2026
22Radnor Capital Management, LLC15,0000 (0.00%)0.02%$0 MOct 23, 2026
23Vanguard Global Advisers, LLC14,8670 (0.00%)0.02%$0 MNov 13, 2026
24Daniel Investment Group, Inc.13,0760 (0.00%)0.01%$0 MNov 13, 2026
25Tower Research Capital LLC (TRC)10,050New0.01%$0 MNov 16, 2026
Show all 32: investors 26 to 32
Institutional investors 26 to 32 in Milestone Scientific Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Oppenheimer & Co Inc10,0000 (0.00%)0.01%$0 MOct 26, 2026
27UBS Group AG4,986-3,604 (-41.96%)0.01%$0 MNov 10, 2026
28Morgan Stanley1,953-1,058 (-35.14%)0.00%$0 MNov 13, 2026
29Royal Bank Of Canada549New0.00%$0 MNov 16, 2026
30Jpmorgan Chase & Co2200 (0.00%)0.00%$0 MNov 12, 2026
31FMR LLC140New0.00%$0 MNov 10, 2026
32Citigroup Inc1New0.00%$0 MNov 4, 2026

Mutual funds holding Milestone Scientific Inc.#

7 funds hold shares worth $1 M (about 3.0% of the company). Since their previous reports 1 added shares and 2 sold, buying $0 M net.
Mutual funds holding Milestone Scientific Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.45 M$0 M1.6%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.611,482$0 M0.69%<0.01%+17%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC330,613$0 M0.37%<0.01%−0.8%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC101,876$0 M0.11%<0.01%no changeMay 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC99,500$0 M0.11%0.02%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC72,271$0 M0.08%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.10,938$0 M0.01%<0.01%−2.7%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Milestone Scientific Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
16
since
-$201 K$0Aug 2024: bought $0 (0 trades), sold $135 K (1 trades)Aug 24Sep 2024: bought $0 (0 trades), sold $3 K (3 trades)Oct 2024: bought $0 (0 trades), sold $100 K (1 trades)OctDec 2024: bought $0 (0 trades), sold $16 K (1 trades)May 2025: bought $0 (0 trades), sold $28 K (3 trades)MayJun 2025: bought $0 (0 trades), sold $201 K (15 trades)Jul 2025: bought $0 (0 trades), sold $69 K (4 trades)JulSep 2025: bought $0 (0 trades), sold $6 K (1 trades)Oct 2025: bought $0 (0 trades), sold $168 K (12 trades)Oct
Bought (open market)Sold (open market)Hover a month for the totals
Milestone Scientific Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed S.r.l. Bp410% ownerSell-100,000$0.440$44 K8.90 MForm 4
filed S.r.l. Bp410% ownerSell-80,000$0.430$34 K9.00 MForm 4
filed S.r.l. Bp410% ownerSell-14,427$0.450$6 K9.08 MForm 4
filed S.r.l. Bp410% ownerSell-40,000$0.440$18 K9.09 MForm 4
filed S.r.l. Bp410% ownerSell-24,034$0.450$11 K9.13 MForm 4
filed S.r.l. Bp410% ownerSell-30,000$0.540$16 K9.16 MForm 4
filed S.r.l. Bp410% ownerSell-10,000$0.550$6 K9.18 MForm 4
filed S.r.l. Bp410% ownerSell-10,158$0.550$6 K9.19 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Milestone Scientific Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
78,756
0.1% of shares · 1 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 172 shares at $0.34
  • : 373 shares at $0.41
  • : 385 shares at $0.42
  • : 1,176 shares at $0.42
  • : 446 shares at $0.47

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Milestone Scientific Inc. scorecard#

Passes 4 of the 20 checks that could be worked out: strongest in growth (2 of 6), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 14, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median11.0×Price to book 11.0× against Medical Instruments's median of 3.9×.
    • ✗Price to sales below its peers' median3.3×Price to sales 3.3× against Medical Instruments's median of 3.0×.
    • ✗Free cash flow yield above 5%-9.5%Free cash flow is -9.5% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 4.92% (2026-11-20).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth2 of 6
    • ✓Revenue grew in the newest year3.9%Revenue up 3.9% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years0.6%0.6% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median0.6%0.6% a year against Medical Instruments's median of 5.0% (37 companies).
    • ✗Earnings per share grew in the newest year-0.07 vs -0.06Diluted EPS -0.07 in fiscal 2025 against -0.06 the year before (report's currency).
    • ✓Net income higher than five years earlier-$6 M-$6 M in fiscal 2025 against -$7 M in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$6 MNet income -$6 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-63.5%-63.5% against Medical Instruments's median of 7.2% (46 companies).
    • ✗Return on equity above 15%-132.4%-132.4% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-63.5%-63.5% in fiscal 2025 against -100.2% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities1.8×Current ratio 1.81 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-21.02Z-score -21.02 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year2.9%Diluted shares up 2.9% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Instruments, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Milestone Scientific Inc.'s statements, beside the median of Medical Instruments.

Milestone Scientific Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-63.6%7.2%
Net margin-63.8%3.8%
Return on equity-132.4%3.5%
Revenue growth, 3 years a year0.6%5.0%
Revenue growth3.9%8.9%
Free cash flow margin-32.8%6.3%

2of 8on the Piotroski tests of financial strength

  • Net loss of $6 million, the 12th loss-making year in a row.
  • Free cash flow was negative: -$3 million.

Milestone Scientific Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Milestone Scientific Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue9.08.69.88.8105.48.49.61110
Cost of revenue2.62.23.03.94.01.82.75.24.34.2
Gross profit6.46.46.84.96.33.65.74.47.06.3
Research and development0.40.90.71.20.90.30.20.20.31.3
Selling, general and administrative121213131311r9.5111212
Operating expenses1213141414119.7121213
Operating income−5.7−6.8−7.1−8.8−7.4−7.5−4.0−8.0−5.2−6.5
Interest and finance income———————0.00.00.0
Net interest income—0.10.10.1−0.0−0.0r0.00.0——
Share of profit of associates———00.20.10.10.3−0.1−0.8
Other non-operating income (expense)—————−0.0−0.0−0.0−0.0−0.0
Income before tax−5.7−4.7−7.0−8.8−7.1−7.5−7.6−8.0−5.2−6.5
Income tax——000.00.00.00.00.0−0.0
Net income including minority interests—−4.7−7.0−8.8−6.9−7.4−7.6−7.7−5.4−7.3
Minority interests' share of net income—0−0.1−0.1−0.1−0.1−0.1−0.3−0.2−1.3
Net income attributable to shareholders−5.7−4.7−6.9−8.7−6.8−7.3−7.5−7.4−5.2−5.9
Earnings per share, basic-0.07-0.06-0.10-0.12-0.10-0.12-0.16-0.21-0.16-0.22
Earnings per share, diluted-0.07-0.06——-0.10-0.12-0.16-0.21-0.16-0.22
Shares, weighted average (basic)82807371696346353327
Shares, weighted average (diluted)8280——696346353327
Balance sheet
Cash and cash equivalents1.1r3.33.08.715141.52.0r2.63.6
Short-term investments—03.08.715r130.3———
Receivables—0.50.30.70.91.11.72.01.50.8
Inventory3.83.72.61.81.52.41.61.93.44.6
Other current assets0.50.60.50.40.40.40.50.40.40.3
Current assets7.59.3111319196.1r5.91213r
Property, plant and equipment0.00.00.00.00.00.00.00.10.10.2
Right-of-use (leased) assets0.20.30.40.40.5r0.6r0.0r———
Other intangible assets0.10.10.20.20.30.30.40.42.80.7
Total assets7.89.8111420206.66.41614r
Accounts payable———1.10.80.51.41.1r1.0r1.3r
Current liabilities3.9r3.73.13.33.12.94.94.96.75.6r
Lease liabilities (non-current)0.00.20.30.40.50.6————
Total liabilities4.8r4.03.43.73.63.54.94.98.15.6
Retained earnings−134r−128−123−116−108−101−94−86−79−73
Shareholders' equity3.0r5.88.01016161.71.57.28.5
Minority interests——0−0.2−0.2−0.1−0.1−0.00.30.0
Total equity—5.88.01016161.61.57.58.5
Total liabilities and equity7.89.8111420206.66.41614r
Shares outstanding80787669686449343330
Cash-flow statement
Depreciation and amortization0.10.00.10.10.10.10.10.90.6—
Share-based compensation1.01.31.51.50.80.60.20.40.71.9
Cash from operating activities−2.9−2.9−5.3−6.0−4.0r−7.0−1.8−1.6−1.2−5.4
Capital expenditure−0.0−0.0—−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Intangible assets bought————————−0.0−0.0
Cash from investing activities−0.03.0−3.0−0.0−0.0−0.0−0.0−0.0−0.20.0
Debt issued0.8—————————
Shares issued——2.600182.0—0.22.6
Cash from financing activities0.80.22.6−0.04.6r202.6−0.30.54.8
Change in cash−2.10.3−5.7−6.00.5130.8−1.9−1.0−0.6
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Milestone Scientific Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Handpieces$7 M80%
  • Instruments$2 M20%
  • Other$0 M0.8%

Business segments

  • Dental$9 M98%
  • Dental$9 M98%
  • Medical$0 M2.0%
  • Medical$0 M2.0%

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Milestone Scientific Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.

Milestone Scientific Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office2 subsidiaries$5 M55%
🇨🇳 China$0 M3.5%

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Milestone Scientific Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$795 K
Other top executives, average
$497 K
the CEO earned 1.6× this
$100 invested is now
$29
Milestone Scientific Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Chief executive$795 K$77 K$497 K$29
2024Chief executive$881 K$881 K—$137
2023Chief executive$680 K$680 K—$150

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Milestone Scientific Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling
  • Delisting noticeFiling
  • Auditor changedFiling

Delisting notice 1 · Auditor changed 2 · Directors and officers 8 · Material agreement 7 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3

Milestone Scientific Inc.: events reported to the SEC
FiledWhat happenedFiling
Directors and officersShareholder vote8-K
Directors and officersMaterial agreement8-K
Directors and officers8-K
Auditor changed8-K
Material agreementUnregistered share sale8-K
Material agreement8-K
Bylaws or fiscal year changed8-K
Material agreement8-K
Shareholder vote8-K
Directors and officers8-K
Delisting notice8-K
Directors and officers8-K
Directors and officers8-K
Auditor changed8-K
Directors and officers8-K
Directors and officers8-K
Shareholder vote8-K
Material agreement8-K
Material agreement8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Jul 31, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Milestone Scientific Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2026$2 MPrivate placement after listing$2 to $10 million21equity, optionsSEC
May 2014$10 MNo. 1$10 to $50 million1equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Product recalls by Milestone Scientific Inc.#

1 recalls since 2015, 165,850 units in the notices that give a number. Medical devices (FDA): 1.

Milestone Scientific Inc.: product recalls
DateWhat and whyUnitsNotice
Milestone Wand STA Handpiece for the delivery of local anesthesia to dental tissue. Model Number STA-5050-305. The Wand STA handpiece is a single use syringe used in conjunction with the CompuDent STA computer controlled dental injection system.Wand Handpiece was mislabeled as STA handpiece. The Wand handpiece cannot be installed in the STA instrument.Medical devicesClass III165,850Z-1952-2015

Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness

How Milestone Scientific Inc. compares in Medical Instruments

  • Market cap$31 M · higher than 4% of 116
  • Revenue$9 M · higher than 7% of 120
  • Net margin-44.1% · higher than 5% of 114
  • Revenue growth3.9% · higher than 27% of 49
  • Price / sales3.3× · lower than 46% of 85
  • Price / book11.0× · lower than 7% of 84
  • FCF yield-9.5% · higher than 21% of 39

Peer comparison · Medical Instruments

CompanyMarket capP/ENet marginRev. growth
Milestone Scientific Inc.🇺🇸$31 M—-44.1%+3.9%
Intuitive Surgical, Inc.🇺🇸$155.6 B52.6×25.5%+20.5%
EssilorLuxottica S.A.🇫🇷$88.0 B32.1×8.1%+4.5%
HOYA Corporation🇯🇵$56.2 B32.8×25.4%—
Becton, Dickinson and Company🇺🇸$54.0 B57.4×4.2%+8.2%
Alcon Inc.🇨🇭$37.1 B37.9×9.4%+4.9%
ResMed Inc.🇺🇸$35.3 B22.1×27.8%+9.8%
West Pharmaceutical Services, Inc.🇺🇸$27.1 B42.4×18.8%+6.3%
Terumo Corporation🇯🇵$24.9 B27.0×12.0%—

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 14, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 21, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Milestone Scientific Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Milestone Scientific Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Milestone Scientific Inc.? Suggest a correction